PMID- 21036723
OWN - NLM
STAT- MEDLINE
DCOM- 20101210
LR  - 20141120
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 30
IP  - 10
DP  - 2010 Oct
TI  - Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization 
      and immunohistochemistry in saudi female breast cancer.
PG  - 4081-8
AB  - BACKGROUND: Amplification of the HER-2/neu oncogene and concomitant 
      over-expression of its protein are detected in approximately 18% of invasive 
      ductal carcinoma of the breast and is associated with poor prognosis. This study 
      tested the use of fluorescence in situ hybridization (FISH) and 
      immunohistochemistry (IHC) to evaluate the HER-2/neu gene status and to ascertain 
      the concordance rate between the two methods. PATIENTS AND METHODS: Eighty two 
      tumour samples containing representative tumour were divided for testing using 
      each assay. HER-2/neu gene amplification is scored as a ratio of HER-2/neu gene 
      amplification to chromosome 17. The ratio should be >2.2 to be considered as 
      positive. 20 cells should be counted and an average score taken. An extra 20 
      cells should be counted if the ratio is between 1.8-2.2. RESULTS: Seventy five 
      effective samples were used. HER-2/neu gene was amplified in 19 out of 75 cases 
      (25%) whereas, HER-2 protein, by IHC was over-expressed in 18 out of 75 cases 
      (24%). In the 44 negative cases by IHC analysis only 7 cases (16%) of them showed 
      amplification by FISH. Three out of 13 cases (23 %) scored as +2 showed gene 
      amplification by FISH while 9 cases out of 18 cases (50%) were scored as +3. High 
      concordance with FISH results 37:44 (84 %) was noted in negative cases (0/+1 
      cases), while lower concordance 3:13 (23 %) was seen in +2 cases. CONCLUSION: 
      This study revealed a significant concordance between FISH results and IHC 
      results. The study also showed that HER2/neu amplification is higher in Saudi 
      patients than other western populations. However, due to the inherent failures of 
      the IHC assay, FISH should always be used when the IHC results are inconclusive. 
      The rational algorithm for HER-2/neu testing would be to perform IHC first, 
      followed by FISH to validate equivocal IHC results.
FAU - Al-Khattabi, Heba
AU  - Al-Khattabi H
AD  - Center of Excellence in Genomic Medicine Research, KFMRC, King Abdulaziz 
      University, Jeddah, Saudi Arabia.
FAU - Kelany, Abdelhakeem
AU  - Kelany A
FAU - Buhmeida, Abdelbaset
AU  - Buhmeida A
FAU - Al-Maghrabi, Jaudah
AU  - Al-Maghrabi J
FAU - Lari, Sahira
AU  - Lari S
FAU - Chaudhary, Adeel
AU  - Chaudhary A
FAU - Gari, Mamdooh
AU  - Gari M
FAU - Abuzenadah, Adel
AU  - Abuzenadah A
FAU - Al-Qahtani, Mohmmad
AU  - Al-Qahtani M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*enzymology/*genetics
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Receptor, ErbB-2/biosynthesis/*genetics
MH  - Saudi Arabia
MH  - Young Adult
EDAT- 2010/11/03 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/11/02 06:00
PHST- 2010/11/02 06:00 [entrez]
PHST- 2010/11/03 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 30/10/4081 [pii]
PST - ppublish
SO  - Anticancer Res. 2010 Oct;30(10):4081-8.